期刊文献+

替诺福韦的合成工艺改进 被引量:9

Improvement of synthetic process of tenofovir
暂未订购
导出
摘要 目的:改进替诺福韦的合成工艺。方法:以亚磷酸二乙酯和多聚甲醛经缩合、酯化得到对甲苯磺酸羟甲基磷酸二乙基酯(4)。另以缩水甘油合成碳酸丙烯酯,与腺嘌呤反应得到9-(2-羟丙基)腺嘌呤(7),在叔丁醇钠作用下与(4)经缩合、水解等反应制得抗病毒药物替诺福韦。结果:优化后的制备工艺成本低,操作简便,对环境污染减少。结论:新工艺的产率达到30%,适合工业生产。 Objective: To improve the synthetic process of tenofovir. Methods: P-toluenesulfonic acid diethoxyphosphorylmethyl ester(4) was prepared from diethyl phosphate and paraformaldehyde by condensation and esterification. 9-(2-hydroxy- propyl)adenine (7) was synthesized by reaction of adenine and propylene carbonate. In presence of ( CH3 )3 CONa, compound (7) was connected with compound (4), and then hydrolyzed to tenofovir. Results:The technique was successfully improved due to its low cost, easier operation and less pollution to the environment. Conclusion: The overall yield of the improved synthetic process was 30% , which is more suitable for industrial production.
出处 《药学实践杂志》 CAS 2009年第1期31-32,45,共3页 Journal of Pharmaceutical Practice
关键词 替诺福韦 合成 工艺改进 tenofovir synthesis technical improvement
  • 相关文献

参考文献6

  • 1崔岚,安富荣,王晓珉.核苷酸逆转录酶抑制剂替诺福韦DF[J].中国新药杂志,2004,13(11):1054-1058. 被引量:30
  • 2Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamies in HlV-hepatitis B virus-coinfected patients treated with tenofovir disoproxil fumarate [ J ]. AIDS, 2005, 19 (9) : 907.
  • 3Van BF, Wunsche T, Mauss S, et al. Comparision of adefovir and tenofovir in the treatment of lamivudine - resistant hepatitis B virus infection [ J ]. Hepatology, 2004, 40 ( 6 ) : 1421.
  • 4Sorbera LA, Castanet J. ( R)-PMPA and Bis(POC) PMPA[ J]. Drugs Fur, 1998, 23(12) :1279.
  • 5Holy A, Dvorakova H, DeClercq E, et al. Antiretroviral enantiomerle nucleotide analogs[ P]. WO 9403467.
  • 6Schultze LM, Chapman HH, Dubree NJP, et al. Practical synthesis of the anti-HIV drug, PMPA[ J]. Tetrahedron Lett, 1998, 39(14) : 1853.

二级参考文献16

  • 1[1]Robbins BL,Srinivas RV,Kim C,et al.Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA),Bis(isopropyloxymethylcarbonyl)PMPA[J].Antimicrob Agents Chemother,1998,42(3):612-617.
  • 2[2]Arimilli MN,Kim CU,Dougherty J,et al.Synthesis,in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs[J].Antivir Chem Chemother,1997,8(6):557-564.
  • 3[3]Hossain MM,Coull JJ,Drusano GL,et al.Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir,didanosine,and tenofovir[J].Antiviral Res,2002,55(1):41-52.
  • 4[4]Cihlar T,Ho ES,Lin DC,et al.Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs[J].Nucleosides Nucleic Acids,2001,20(4-7):641-648.
  • 5[5]Zidek Z,Frankova D,Holy A.Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES,macrophage inflammatory protein 1α) and cytokine (tumor necrosis factor α,interleukin-10[IL-10],IL-1β) production[J].Antimicrob Agents Chemother,2001,45(12):3381-3386.
  • 6[6]Van Gelder J,Deferme S,Annaert P,et al.Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism[J].Drug Metab Dispos,2000,28(12):1394-1396.
  • 7[7]Barditch-Crovo P,Deeks SG,Collier A,et al.Phase Ⅰ/Ⅱ trial of the pharmacokinetics,safety,and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults[J].Antimicrob Agents Chemother,2001,45(10):2733-2739.
  • 8[8]Schooley RT,Ruane P,Myers RA,et al.Tenofovir DF in antiretroviral-experienced patients:results from a 48-week,randomized,double-blind study[J].AIDS,2002,16(9):1257-1263.
  • 9[9]Therese M,Chapman,Jane K,et al.Tenofovir disoproxil fumarate[J].Drugs,2003,63(15):1597-1608.
  • 10[10]Squires K,Pozniak AL,Pierone G Jr,et al.Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection:a randomized trial[J].Ann Intern Med,2003,139(5 Pt 1):313-320.

共引文献29

同被引文献51

  • 1崔岚,安富荣,王晓珉.核苷酸逆转录酶抑制剂替诺福韦DF[J].中国新药杂志,2004,13(11):1054-1058. 被引量:30
  • 2唐小平,童裕维.HBV/HIV合并感染的研究进展[J].内科急危重症杂志,2006,12(3):138-141. 被引量:3
  • 3Nunez M,Perez Olmeda M,Diaz B,et al.Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine [J].AIDS,2002,16 (17):2352- 2354.
  • 4F van B?mmel,T Wunsche,S Mauss,et al.Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection[J].Hepatology, 2004,40(6) : 1421-1425.
  • 5F van B?mmel,R De Man,K Stein,et al.A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience[J].J Hepatology,2008,48 (2):S32.
  • 6J.D.小蒙格.J.C.若罗夫.L.M.舒尔兹.含核苷酸类似物的组合物及其合成方法[P].中国专利,CN1251679C,2006-4-19.
  • 7Lisa M. Schultze,Harlan H. Chapman,Nathan J. P. Dubree,et al. Practical synthesis of the anti-HIV drug, PMPA[J].Tetrahedron Letters, 1998,39( 14 : 1853-1856.
  • 8Bischofberger N W.PMPA preparation [P].USA ,US5733788,1998- 03-3.
  • 9Murty N. Arimilli,Kenneth C. Cundy,Joseph P. Dougherty,et al. Antiviral phosphonmethyoxy nucleotide analogs having increased oral bioavarilability[P].USA ,US5922695,1999-07-13.
  • 10Mehellou Y, Clercq E D. Twenty-six years of anti-HIV drug discovery:Where do we stand and where do we go[J]. Journal of Medicinal Chemistry, 2010,53 (2) : 521-538.

引证文献9

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部